Kidney transplant virus filter trial pulled before start
NCT ID NCT04984902
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aimed to see if a special blood filter (Seraph 100) could reduce BK virus levels in kidney transplant patients with high viral loads. It planned to enroll adults with a BK virus level of 10,000 IU/mL or higher who already had dialysis access. However, the trial was withdrawn before any participants were enrolled, so no results are available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Expected to start
-
Feb 2022
An estimate. Start dates often move.
- Expected to finish
-
Apr 2023
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 90 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Kidney transplant patients with a BK-viraemia ≥ 10,000 IU/ml. 2. Be ≥ 18 years old and ≤ 90 years old 3. Existing hemodialysis access Exclusion Criteria: 1. Subject is currently participating in another clinical investigation 2. Pregnant or nursing subjects and those who plan pregnancy during the clinical investigation follow-up period 3. Presence of comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results 4. Have Child-Pugh Class C cirrhosis 5. Have platelet count \<30.000/uL 6. Contraindications for heparin sodium for injection 7. Subjects demonstrating any contraindication for this treatment as described in the IFU 8. Patients without existing hemodialysis access
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BK viremia in kidney transplant patients are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Hospital Essen
Essen, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Chilling donors: can cooling Brain-Dead organ donors make kidney transplants work better?
- Muscle therapy may restore strength in dialysis patients
- Can software make hospital pharmacists faster and safer?
- Could a blood pressure pill shield blood vessels from heart attacks?
- A new tool to predict kidney failure risk in membranous nephropathy?
- Blood markers may foretell kidney trouble in lupus